Printer Friendly

DNX NAMES BAXTER EXECUTIVE TO NEW BOARD SEAT

 PRINCETON, N.J., Oct. 11 /PRNewswire/ -- DNX Corporation (NASDAQ: DNXX) today announced the appointment of Baxter executive Dale A. Smith to the company's board of directors. This appointment increases the number of board members to ten.
 "Mr. Smith's 31 years of experience at Baxter International, particularly his time heading the biotechnology group, will be a tremendous asset to DNX," said Paul J. Schmitt, president and chief executive officer of DNX. "Dale has been especially pro-active in his support of xenotransplantation, and we will benefit from his guidance as we advance toward the clinic."
 Mr. Smith is group vice president of Baxter International, having served in that capacity since 1979. At Baxter, Mr. Smith has been responsible for the biotechnology group and various corporate research groups including applied sciences, blood substitutes group, venture technology and Baxter's European Research Center in Nivelles, Belgium. In addition, Mr. Smith has held various sales and marketing positions at Baxter including president of the Fenwal division and president of the parenterals division.
 "I was attracted to DNX because of its cutting-edge technology and the caliber of its management team," said Mr. Smith. "The scientific focus of DNX, especially the application of using genetically engineered swine as a source of permanent organ transplants for humans, is quite fascinating, and I look forward to contributing to the future of the company."
 Mr. Smith is an at-large director of the American Blood Commission and a former member of the Blood Services Board of the Mid-America Chapter of the American Red Cross and LifeSource Blood Services of Chicago. In addition to DNX, Mr. Smith is a member of the board of directors of Neocrin, Inc. and a former board member of Applied Immune Sciences.
 DNX Corporation is a life sciences company operating through two wholly owned subsidiaries. DNX Biotherapeutics, Inc. is a leader in the research and development of organ transplantation products largely based on transgenic animal technology. Pharmakon Research International is a leading supplier of preclinical and biological testing services to the biotechnology, pharmaceutical and chemical industries.
 -0- 10/11/93
 /CONTACT: Paul J. Schmitt, president and CEO of DNX Corporation, 609-520-0300, or Anthony J. Russo, Ph.D., or Rhonda Chiger of Noonan/Russo Communications, 212-696-4455/
 (DNXX)


CO: DNX Corporation ST: New Jersey IN: MTC SU: PER

TS-PS -- NY025 -- 0628 10/11/93 11:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 11, 1993
Words:387
Previous Article:GRC INTERNATIONAL, INC. ANNOUNCES FIVE DOD PRIME CONTRACT WINS WITH POTENTIAL REVENUES OF UP TO $37 MILLION
Next Article:PARAMOUNT COMMUNICATIONS ISSUES STATEMENT ON QVC FINANCING DOCUMENTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters